Last reviewed 2026-04-20 · How we verify

Cosentyx

At a glance

Approved indications

• Ankylosing spondylitis
• Non-radiographic axial spondyloarthritis
• Plaque psoriasis
• Psoriatic arthritis
• Pustular psoriasis

Common side effects

• Infections
• Nasopharyngitis
• Diarrhea
• Upper respiratory tract infection

Serious adverse events

• Serious infections
• Inflammatory bowel disease (IBD)
• Sepsis
• Neutropenia

Key clinical trials

• Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients (PHASE2)
• A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy (PHASE3)
• Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients (PHASE4)
• Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy (PHASE3)
• Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa (PHASE4)
• Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (PHASE4)
• Psoriasis Longitudinal Assessment and Registry
• IL-17 Blockade to Decrease irAEs (REPLAY) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Cosentyx CI brief — competitive landscape report
• Cosentyx updates RSS · CI watch RSS
• Janssen Research & Development, LLC portfolio CI